Expression of ERK1 and ERK2 in prostate cancer

  • Norelia Torrealba Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Benito Fraile Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Gabriel Olmedilla Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Pilar Martínez-Onsurbe Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Manuel Guil-Cid Department of Urology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Ricardo Paniagua Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Mar Royuela | mar.royuela@uah.es Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.

Abstract

Prostate cancer may emerge as result of dysregulated balance between cell proliferation and death rates, increased angiogenesis and chronic. These processes are regulated by numerous signaling proteins, including the mitogen-activated protein kinases (MAPKs). JNK, p38 and extracellular signal-regulated kinase (ERK) are the three major sub-families of MAPKs. The pro-oncogenic effects of ERK isoforms (ERK1 and ERK2) lie in their aberrant activation through phosphorylation by any mutation along the pathway of receptor tyrosine kinase (RTK)-Ras-Raf-MEK-ERK1/2. Once activated, ERKs phosphorylate cytoskeletal proteins, kinases, and transcription factors. Active ERK proteins induce strong proliferative and anti-apoptotic effects. Our group has tested variations in expression, activation and localization of ERKs in human prostate. Differential ERK1/2 expression and phosphorylation status may be linked to the progression of prostate cancer. The major striking observation is that ERKs are expressed in tumors with higher proportion than normal prostate. We believe that this is an important notion because the status (expression, localization, phosphorylation and the ERK1/ERK2 ratio) of ERK in the prostate may be developed into an important prognostic marker that predicts patient responce to the anti-cancer treatment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2015-12-18
Info
Issue
Section
Review Articles
Supporting Agencies
“Instituto de Salud Carlos III” (PI13/01801) of Spain.
Keywords:
MAPKs, ERK1, ERK2, p-ERK and prostate cancer.
Statistics
  • Abstract views: 3085

  • PDF: 669
How to Cite
Torrealba, N., Fraile, B., Olmedilla, G., Martínez-Onsurbe, P., Guil-Cid, M., Paniagua, R., & Royuela, M. (2015). Expression of ERK1 and ERK2 in prostate cancer. MAP Kinase, 4(1). https://doi.org/10.4081/mk.2015.5265